Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives Consensus Rating of “Moderate Buy” from Brokerages

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has received a consensus rating of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $2.18.

Several research analysts have recently commented on ADAP shares. StockNews.com began coverage on Adaptimmune Therapeutics in a research report on Friday. They issued a “buy” rating for the company. Mizuho cut their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research report on Friday. Finally, Scotiabank decreased their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research report on Friday.

Adaptimmune Therapeutics Stock Up 3.9 %

ADAP stock traded up $0.01 during trading on Friday, hitting $0.29. 4,999,050 shares of the company’s stock traded hands, compared to its average volume of 1,407,286. The business has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.71. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $74.41 million, a P/E ratio of -1.32 and a beta of 2.52. Adaptimmune Therapeutics has a 1 year low of $0.26 and a 1 year high of $1.65.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Two Seas Capital LP purchased a new stake in shares of Adaptimmune Therapeutics during the fourth quarter valued at $7,992,000. Long Focus Capital Management LLC raised its stake in Adaptimmune Therapeutics by 54.1% in the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock worth $11,040,000 after acquiring an additional 7,194,503 shares during the last quarter. Renaissance Technologies LLC lifted its position in Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock worth $1,361,000 after acquiring an additional 869,949 shares during the period. Jane Street Group LLC grew its stake in Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 152,780 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at about $95,000. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.